<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/30B60FAC-E491-4CFB-9B10-9FCD4642CBAE"><gtr:id>30B60FAC-E491-4CFB-9B10-9FCD4642CBAE</gtr:id><gtr:name>Cambivac Ltd</gtr:name><gtr:address><gtr:line1>CPC 1 CAPITAL PARK , FULBOURN</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB21 5XE</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30B60FAC-E491-4CFB-9B10-9FCD4642CBAE" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>30B60FAC-E491-4CFB-9B10-9FCD4642CBAE</gtr:id><gtr:name>Cambivac Ltd</gtr:name><gtr:address><gtr:line1>CPC 1 CAPITAL PARK , FULBOURN</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB21 5XE</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>99641.0</gtr:offerGrant><gtr:projectCost>221425.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6CCA5980-E65A-49AB-B095-81EEE3B6A249"><gtr:id>6CCA5980-E65A-49AB-B095-81EEE3B6A249</gtr:id><gtr:firstName>Grant</gtr:firstName><gtr:surname>Austin</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=720438"><gtr:id>6C88F05E-A9EF-4206-BCF7-7DC49226102C</gtr:id><gtr:title>Development of a safe and cost effective vaccine for Foot and Mouth Disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Development of Prototype</gtr:grantCategory><gtr:grantReference>720438</gtr:grantReference><gtr:abstractText>This application is for a Development of Prototype (DoP) grant to undertake technology
optimisation, scale up, and begin clinical testing of prototype vaccines produced utillising our
expression technology which highly efficiently produces improved foot and mouth (FMD)
vaccines without the use of live virus.
The application builds on a Proof of Concept (PoC) project that has shown our novel
approach can synthetically produce the immunogenic structural antigen component of the
FMD virus with orders of magnitude greater yields than is possible with currently marketed
vaccines. Unlike these vaccines which grow and inactivate live FMD virus, our synthetic
antigen, lacking genetic material, carries no risk of causing outbreaks such as the 2007 one in
Pirbright in Surrey.
There is little or no cross-protection across the seven FMD serotypes (A, O, C, Asia 1, Sat 1,
Sat 2 and Sat 3) and a large number of subtypes. This and governmental control has resulted
in dominant regional producers manufacturing vaccines matched to localised circulating field
strains.
Our technology opens up out licensing opportunities in countries where vaccination is
routinely used as a method of controlling FMD in addition to markets such as UK, Europe and
North America where culling is preferred and vaccine stocks are only held for emergencies.
The cost reduction possible with our technology is attractive to vaccine manufacturers
operating in an increasingly cost competitive environment.
The technology would also open up the opportunity for export to international markets from
UK manufacturers, an opportunity not possible with current technology due to high
containment requirement and use of live exotic strains of FMD.
FMD is one of the most economically and socially devastating animal diseases globally and
our technology, combined with other integrated strategies, would have major economic and
social benefit to the UK, EU and many other regions of the world.</gtr:abstractText><gtr:fund><gtr:end>2016-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>99641</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">720438</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>